PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population

PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population

# Background The US population includes 24 million to 29 million people with diagnosed and undiagnosed chronic obstructive pulmonary disease (COPD). Studies have demonstrated the safety and efficacy of single-inhaler triple therapy (SITT) in reducing COPD exacerbations. Long-term population implicat...

Full description

Saved in:
Bibliographic Details
Main Authors: Gerard Criner, Fernando Martinez, Norbert Feigler, Hitesh Gandhi, Bruce Pyenson, Matthew Emery, Umang Gupta, Muthiah Vaduganathan
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2023-01-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.55635
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.36469/001c.55635

Similar Items